These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 27626976)

  • 1. Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study.
    Fiorentini C; Fragni M; Perego P; Vezzoli S; Bonini SA; Tortoreto M; Galli D; Claps M; Tiberio GA; Terzolo M; Missale C; Memo M; Procopio G; Zaffaroni N; Berruti A; Sigala S
    J Clin Endocrinol Metab; 2016 Dec; 101(12):4594-4602. PubMed ID: 27626976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro antitumor activity of progesterone in human adrenocortical carcinoma.
    Fragni M; Fiorentini C; Rossini E; Fisogni S; Vezzoli S; Bonini SA; Dalmiglio C; Grisanti S; Tiberio GAM; Claps M; Cosentini D; Salvi V; Bosisio D; Terzolo M; Missale C; Facchetti F; Memo M; Berruti A; Sigala S
    Endocrine; 2019 Mar; 63(3):592-601. PubMed ID: 30367443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adrenocortical Carcinoma Xenograft in Zebrafish Embryos as a Model To Study the In Vivo Cytotoxicity of Abiraterone Acetate.
    Gianoncelli A; Guarienti M; Fragni M; Bertuzzi M; Rossini E; Abate A; Basnet RM; Zizioli D; Bono F; Terzolo M; Memo M; Berruti A; Sigala S
    Endocrinology; 2019 Nov; 160(11):2620-2629. PubMed ID: 31397841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic Effect of Progesterone, Tamoxifen and Their Combination in Experimental Cell Models of Human Adrenocortical Cancer.
    Rossini E; Tamburello M; Abate A; Beretta S; Fragni M; Cominelli M; Cosentini D; Hantel C; Bono F; Grisanti S; Poliani PL; Tiberio GAM; Memo M; Sigala S; Berruti A
    Front Endocrinol (Lausanne); 2021; 12():669426. PubMed ID: 33981288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abiraterone Acetate for Cushing Syndrome: Study in a Canine Primary Adrenocortical Cell Culture Model.
    Sanders K; de Wit WL; Mol JA; Kurlbaum M; Kendl S; Kroiss M; Kooistra HS; Galac S
    Endocrinology; 2018 Nov; 159(11):3689-3698. PubMed ID: 30219917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nutlin-3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation.
    Hui W; Liu S; Zheng J; Fang Z; Ding Q; Feng C
    Cancer Med; 2018 Apr; 7(4):1440-1449. PubMed ID: 29532999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma.
    Zhu Y; Wang M; Zhao X; Zhang L; Wu Y; Wang B; Hu W
    Oncotarget; 2017 Apr; 8(14):22825-22834. PubMed ID: 28423559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma.
    Satoh K; Zhang L; Zhang Y; Chelluri R; Boufraqech M; Nilubol N; Patel D; Shen M; Kebebew E
    Clin Cancer Res; 2016 Jul; 22(14):3458-66. PubMed ID: 26873959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chloroquine enhances the efficacy of cisplatin by suppressing autophagy in human adrenocortical carcinoma treatment.
    Qin L; Xu T; Xia L; Wang X; Zhang X; Zhang X; Zhu Z; Zhong S; Wang C; Shen Z
    Drug Des Devel Ther; 2016; 10():1035-45. PubMed ID: 27022243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane.
    van Koetsveld PM; Vitale G; Feelders RA; Waaijers M; Sprij-Mooij DM; de Krijger RR; Speel EJ; Hofland J; Lamberts SW; de Herder WW; Hofland LJ
    Endocr Relat Cancer; 2013 Jun; 20(3):443-54. PubMed ID: 23507702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the Tcf/beta-catenin complex increases apoptosis and impairs adrenocortical tumor cell proliferation and adrenal steroidogenesis.
    Leal LF; Bueno AC; Gomes DC; Abduch R; de Castro M; Antonini SR
    Oncotarget; 2015 Dec; 6(40):43016-32. PubMed ID: 26515592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer.
    Laha D; Grant RRC; Mishra P; Boufraqech M; Shen M; Zhang YQ; Hall MD; Quezado M; De Melo MS; Del Rivero J; Zeiger M; Nilubol N
    J Exp Clin Cancer Res; 2022 Sep; 41(1):282. PubMed ID: 36151566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells.
    De Martino MC; van Koetsveld PM; Feelders RA; Sprij-Mooij D; Waaijers M; Lamberts SW; de Herder WW; Colao A; Pivonello R; Hofland LJ
    Endocr Relat Cancer; 2012 Jun; 19(3):351-64. PubMed ID: 22420007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.
    Durand J; Lampron A; Mazzuco TL; Chapman A; Bourdeau I
    J Clin Endocrinol Metab; 2011 Jul; 96(7):E1206-11. PubMed ID: 21565795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin as a new anti-cancer drug in adrenocortical carcinoma.
    Poli G; Cantini G; Armignacco R; Fucci R; Santi R; Canu L; Nesi G; Mannelli M; Luconi M
    Oncotarget; 2016 Aug; 7(31):49636-49648. PubMed ID: 27391065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 3D adrenocortical carcinoma tumor platform for preclinical modeling of drug response and matrix metalloproteinase activity.
    Dedhia PH; Sivakumar H; Rodriguez MA; Nairon KG; Zent JM; Zheng X; Jones K; Popova LV; Leight JL; Skardal A
    Sci Rep; 2023 Sep; 13(1):15508. PubMed ID: 37726363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel heat shock protein 90 inhibitor potently targets adrenocortical carcinoma tumor suppression.
    Wang T; Subramanian C; Blagg BSJ; Cohen MS
    Surgery; 2020 Jan; 167(1):233-240. PubMed ID: 31561992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumoral effects of 9-cis retinoic acid in adrenocortical cancer.
    Szabó DR; Baghy K; Szabó PM; Zsippai A; Marczell I; Nagy Z; Varga V; Éder K; Tóth S; Buzás EI; Falus A; Kovalszky I; Patócs A; Rácz K; Igaz P
    Cell Mol Life Sci; 2014 Mar; 71(5):917-32. PubMed ID: 23807211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting estrogen receptor-α reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment.
    Sirianni R; Zolea F; Chimento A; Ruggiero C; Cerquetti L; Fallo F; Pilon C; Arnaldi G; Carpinelli G; Stigliano A; Pezzi V
    J Clin Endocrinol Metab; 2012 Dec; 97(12):E2238-50. PubMed ID: 23074235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human adrenal corticocarcinoma NCI-H295R cells produce more androgens than NCI-H295A cells and differ in 3beta-hydroxysteroid dehydrogenase type 2 and 17,20 lyase activities.
    Samandari E; Kempná P; Nuoffer JM; Hofer G; Mullis PE; Flück CE
    J Endocrinol; 2007 Dec; 195(3):459-72. PubMed ID: 18000308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.